Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
REDWOOD CITY, Calif., May 25, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions highlighting the company’s Lumivascular™ technology at the upcoming New Cardiovascular Horizons conference taking place next week in New Orleans from Tuesday, May 30, through Friday, June 2, 2017.
Avinger Lumivascular technology highlights include the following presentations by Patrick Muck, M.D., vascular surgeon at Good Samaritan Hospital in Cincinnati, Ohio:
Tuesday, May 30
- “Optical Coherence Tomography (OCT): Role in Modern Cath Lab,” Crescent City Ballroom, 12:50 – 1:00pm CT
Wednesday, May 31
- “First Look: 24-Month Outcomes from the Pivotal VISION Trial for OCT-Guided Directional Atherectomy,” Waldorf Astoria Ballroom, 11:20 – 11:28pm CT
Thursday, June 1
- “Minimally Invasive Endarterectomy: Using Optical Coherence Tomography (OCT) to Guide Precision Debulking,” Crescent City Ballroom, 8:24 – 8:32pm CT
Materials related to certain sessions listed above will be posted to Avinger’s website following their presentation at the conference.
About Avinger, Inc.
Avinger, Inc. is dedicated to radically changing the way peripheral artery disease (PAD) is treated. The company’s Lumivascular platform, the first-ever image-guided catheter-based systems to diagnose and treat patients with PAD, includes the Lightbox imaging console, the Ocelot family of catheters for chronic total occlusions, and the Pantheris® atherectomy device. Avinger is based in Redwood City, Calif. For more information, please visit www.avinger.com.
Public Relations Contact: Phil Preuss Avinger, Inc. (650) 241-7900 [email protected] Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
